Press Releases

November 06, 2015  BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro Cell Biology Market

ALAMEDA, Calif. & MEDFORD, Mass., November 06, 2015  BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company, and Hepregen Corporation, a privately held company engaged in the development and marketing of proprietary drug screening products, today announced the formation of Ascendance Biotechnology, Inc. (“Ascendance”). Ascendance combines Hepregen’s application-directed, cellular micro-patterning drug and chemical screening technologies with BioTime’s ESI BIO research products and proprietary stem cell technologies. This asset combination will allow Ascendance to offer a broad portfolio of current and new stem-cell-derived assays and other products and services to Hepregen’s major pharmaceutical and chemical company customers. PDF

 

June 23, 2015 SOLVO Biotechnology and Hepregen Corporation Execute Co-marketing Agreement

Glasgow, Scotland, June 23, 2015 – SOLVO Biotechnology and Hepregen Corporation announced today, at the 13th European Meeting of the International Society for the Study of Xenobiotics (“ISSX”), a co-marketing agreement between the companies. This agreement provides for the European marketing of Hepregen’s human, monkey, rat and dog application-directed HepatoPac® and HepatoMune® kits, which are used for liver metabolite analysis, transport studies and predictive and mechanistic toxicology studies. These kits contain human or animal hepatocytes (liver cells) in Hepregen’s proprietary micro-patterned, co-culture microtiter tissue culture plates. This agreement provides SOLVO with the opportunity to provide services to its customers using these Hepregen products as well as HepatoPac® B-CLEAR® products co-developed by Hepregen and Qualyst Transporter Solutions. PDF

 

May, 2015 SCIEX and Hepregen Announce Co-Marketing Agreement for Comprehensive Metabolite Identification Solution

Framingham and Medford, MA – May 15, 2015SCIEX, a global innovator in life science analytical technologies and Hepregen Corporation, a leader in the development of next-generation, application-directed cell-based in vitro assay products, today announced a Co-Marketing Agreement to cooperatively deliver a new metabolite identification (Met ID) solution for drug metabolism scientists. From cell culture to interpretation, this solution provides an extensive view into in vitro data to enable researchers to generate, identify and analyze metabolites in one simple workflow. Customers are guided through the entire workflow, including report generation, with an easy-to-use software solution from start to finish.

This Met ID solution mitigates the chances of downstream drug failure for customers, resulting in higher success rates for drug candidate selection, ensuring that an important metabolite will not be missed. PDF

 

April 20, 2015 Qualyst Transporter Solutions, LLC and Hepregen Corporation Launch HepatoPac® B-CLEAR® Transporter Product

Baltimore, MD, April 20, 2015 – Qualyst Transporter Solutions, LLC (Qualyst) and Hepregen Corporation announced today, at the American Association of Pharmaceutical Scientists/International Transporter Consortium (“AAPS/ITC”) Joint Workshop on Drug Transporters, the launch of their first co-developed and co-labeled transporter kit for in vitro analysis of chemical transporter proteins in the human liver.  The launch of this first application-directed HepatoPac® B-CLEAR® assay kit, provides a product to investigators that can be routinely used for predictive and mechanistic hepatic transporter analysis. This first co-launched kit contains human hepatocytes (liver cells) in Hepregen’s proprietary micro-patterned, co-culture microtiter tissue culture plates and Qualyst’s proprietary transporter culture media. The co-cultures are optimized for transporter analysis using Qualyst’s proprietary hepatobiliary methodology. Moreover, as a part of this launch effort, both companies are continuing their commitment to providing unequaled customer support. Hepregen scientists bring years of experience evaluating metabolite and toxicology data developed using the HepatoPac® platform, and Qualyst scientists provide a wealth of experience interpreting results of measuring concentrations of new chemical entities and their metabolites inside hepatocytes, bile canaliculi and cell culture medium. PDF


January 29, 2015 Hepregen Launches First Dog HepatoPac Assay Kit to Evaluate Metabolism in the Laboratory 

Today, Hepregen Corporation, a leader in the development of next generation HepatoPac® and HepatoMune™ cell-based in vitro assay products announced the commercial launch of the company’s first dog HepatoPac kit designed specifically for metabolite identification and profiling applications. Each kit contains one or more standard 24-well tissue culture plates featuring uniquely configured micro-patterned dog liver cells co-cultured with specially selected stromal cells that support the highest level of performance observed in Hepregen’s micro-patterned co-culture platform. The dog liver cells (hepatocytes) on these plates mirror the behavior of liver cells in live animals, enabling scientists to generate data that can be useful for evaluation of the metabolism of chemical agents, including drug candidates, improving the design of preclinical experiments. PDF

 

October 21, 2014 Qualyst Transporter Solutions, LLC and Hepregen Corporation Execute Co-Development and Co-Marketing Agreement

Qualyst Transporter Solutions, LLC and Hepregen Corporation announced today, at the 19th North American Meeting of the International Society for the Study of Xenobiotics ("ISSX"), the execution of a co-development and co-marketing agreement between the companies. This agreement supports the co-development of HepatoPac® B-Clear® assay kits, which can be used for predictive and mechanistic hepatic transporter analysis. The kits will be marketed by both companies and will contain human or animal hepatocytes (liver cells) in Hepregen’s proprietary micro-patterned, co-culture microtiter tissue culture plates. The co-cultures will be optimized for transporter analysis using Qualyst’s proprietary hepatobiliary methodology and unique capability of measuring intracellular concentrations.   PDF

September 9, 2014 Inventor Creates Tiny Technologies for Medicine; Awarded $500,000 Lemelson-MIT Prize

Dr. Sangeeta Bhatia, biomedical engineer and professor at MIT, is the recipient of the 2014 $500,000 Lemelson-MIT Prize. Bhatia is recognized for designing and commercializing miniaturized technologies with applications to improve human health. The Lemelson-MIT Prize, celebrating its 20th year, honors outstanding mid-career inventors improving the world through technological invention and demonstrating a commitment to mentorship in science, technology, engineering and mathematics. PDF

May 21, 2014 Hepregen Launches First Rat HepatoPac® Assay Kit to Evaluate Hepatotoxicity in the Laboratory

Today at its first annual Mid-Atlantic User Group Meeting, Hepregen Corporation, a leader in the development of next generation HepatoPac® and HepatoMune™ cell-based in vitro assay products announced the commercial launch of the company’s first rat HepatoPac® kit designed specifically for toxicology applications. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned rat liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in live animals, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents (including drug candidates) and improve design of preclinical experiments for drug development. The application-directed kit also provides a tool for the study of the mechanisms leading to such responses. PDF

April 30, 2014 Hepregen Launches Human HepatoMune™ Assay Kit to Evaluate Inflammation-Mediated Hepatotoxicity in the Laboratory

Hepregen Corporation, a leader in the development of next generation HepatoPac® cell-based in vitro assay products today announced the commercial launch of the company’s first human HepatoMune™ micro-liver assay kit. The kit is designed specifically to predict toxicologic outcomes caused by the interaction of drugs and/or biologics with an inflamed liver. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells (hepatocytes) co-cultured with stromal cells to which fully functional human liver immune cells (Küpffer cells) are added. PDF

March 24, 2014 Hepregen Launches First Human HepatoPac® Assay Kit To Evaluate Hepatotoxocity in the Laboratory

Today, at the Society of Toxicology’s 53rd Annual Meeting, Hepregen Corporation, a leader in the development of next generation HepatoPac® and HepatoMune™ cell-based in vitro assay products announced the commercial launch of the company’s first HepatoPac® kit designed specifically for toxicology applications. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates mirror the behavior of liver cells in the body, enabling scientists to generate data that can be useful for prediction of toxic responses to chemical agents, including drug candidates. The application-directed platform also provides a tool for the study of the mechanisms leading to such responses. PDF

March 11, 2014 Hepregen Launches First Human HepatoPac® Assay Kit to Evaluate Metabolic Stability

Hepregen Corporation, a leader in the development of next generation HepatoPac® and HepatoMune™ cell-based in vitro assay products, announced today the commercial launch of the Company’s first HepatoPac® kit designed specifically for use in evaluating metabolic turnover of chemicals in the human liver. The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates remain metabolically active for up to 35 days. Using this plug-in-ready kit, industrial product developers can accurately evaluate metabolic turnover of chemicals regardless of whether they are rapidly or very slowly metabolized by the liver. PDF

February 12, 2014 Hepregen Announces Publication of Several Scientific Papers Providing Evidence of the Unprecedented Utility of its HepatoPac® Products

Hepregen Corporation, leader in the development of next generation HepatoPac® and HepatoMune™ cell-based in vitro assay products, announced today the publication of three scientific papers that demonstrate the unique utility of the Company’s HepatoPac® products for predicting and understanding metabolic and cell transport pathways in both humans and rats, the latter being an important animal model often used for preclinical pharmaceutical development. The papers were published independently by researchers based at Boehringer Ingelheim Pharmaceuticals U.S. research facility located in Ridgeway, Connecticut. They presented data that clearly demonstrated the high correlation of in vitro data with outcomes seen in preclinical animal studies and human clinical trials of the anti-hepatitis C virus (HCV)-directed drug, faldaprevir. These findings included determining the metabolic fate of the drug, identification of two key metabolites, their excretion pathway, and mechanisms of metabolism and transport of metabolites into the bile canaliculi. PDF

October 29, 2013 Hepregen Launches First Monkey HepatoPac® Assay Kits at Annual User Group Meeting

Today, at the Company's annual User Group Meeting, Hepregen Corporation, leader in the development of next generation HepatoPac® and HepatoMune™ cell-based assay products, announced the commercial launch of the Company's first application-oriented, monkey HepatoPac® kits, designed specifically for use in metabolite identification and profiling. The kits contain one or more standard 24-well tissue culture plates containing micro-patterned monkey liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates remain fully functional for up to 35 days. Each of the kits provides customers with a plug-in-ready product that can be used to evaluate metabolite production in monkey liver cells. PDF

September 30, 2013 Hepregen Launches Multi-Donor Human HepatoPac™ Assay Kits at 10th Annual ISSX Meeting

Today, at the annual meeting of the International Society for the Study of Xenobiotics (“ISSX”), Hepregen Corporation, leader in the development of next generation HepatoPac™ and HepatoMune™ cell-based assay products, announced the commercial launch of the Company’s first application-oriented, Triple-Donor Human HepatoPacTM kits designed specifically for use in metabolite identification and profiling. Each kit contains one or more standard 24-well tissue culture plates, each plate containing separately micro-patterned human liver cells called hepatocytes from three individual donors. The hepatocytes on these plates remain fully functional for up to two months. Each of the kits provides customers with a plug-in-ready product that can be used to compare metabolite production in human cells derived from different donors at the same time.  PDF

September 24, 2013 Hepregen Launches First Dual-Species HepatoPac™ DMPK Assay Kits for Metabolite Identification and Profiling

Hepregen Corporation, leader in the development of next generation HepatoPac™ and HepatoMune™ cell-based assay products, announced today the commercial launch of the Company’s first application-oriented, dual-species HepatoPacTM kit designed specifically for use in metabolite identification and profiling. Each kit contains one standard 24-well tissue culture plate, half containing micro-patterned human hepatocytes, and the other half containing micro-patterned rat hepatocytes (available in Wistar-Hahn or Sprague-Dawley strains).  The hepatocytes on these plates from both species remain fully functional for up to two months. These unique dual-species kits provide customers with a plug-in-ready product, designed for use in evaluating metabolite production in a discovery or development setting, or in any case where a quick comparative answer is beneficial.  PDF

September 10, 2013 Hepregen Launches Two Rat HepatoPac™ DMPK Assay Kits for Metabolite Identification and Profiling

Hepregen Corporation, leader in the development of next generation HepatoPacTM and HepatoMuneTM cell-based assay products, announced today the commercial launch of the Company’s first application-oriented Rat HepatoPacTM kits designed specifically for use in metabolite identification and profiling. A kit may be ordered that contains either Wistar-Hahn or Sprague-Dawley rat hepatocytes. Much like the recently introduced Hepregen Human HepatoPacTM kit, each of the kits provides customers with a plug-in-ready product, which includes live rat liver cells on a micro-patterned, standard 24-well tissue culture plate that remain fully functional for more than two months.  PDF

August 27, 2013 Hepregen Launches First Human HepatoPac™ DMPK Assay Kit for Metabolite Identification and Profiling

Hepregen Corporation, developer of next generation HepatoPacTM and HepatoMuneTM products, announced today the commercial launch of the Company’s first application-oriented Human HepatoPacTM Kit designed specifically for use in metabolite identification and profiling. The DMPK Kit, first of its kind, was developed over a 5-year period with significant input from Hepregen’s pharmaceutical company customers and research partners. It provides customers with a plug-in-ready product that includes live, fully functional human liver cells on a micro-patterned, standard 24-well tissue culture plate along with specially formulated tissue culture media for both maintenance and experimental applications. The parenchymal liver cells, known as hepatocytes, remain fully functional in this in vitro co-culture environment for up to eight weeks, allowing for unprecedented and accurate analysis of drug metabolism in both short- and long-term experiments. PDF

August 6, 2013 Hepregen Corporation and the Hamner Institutes for Health Sciences Announce Research Partnership Agreement

Hepregen Corporation, developer of next generation HepatoPacTM and HepatoMuneTM products, and The Hamner Institutes for Health Sciences, a nonprofit research organization focused on translational safety sciences, announced today execution of an agreement that provides for a research partnership between the two entities. The research effort will be led by Dr. Edward LeCluyse, Associate Investigator at The Hamner, and Dr. Michael Holsapple, newly appointed Vice President of Toxicology Product Development at Hepregen, along with Mr. Jack McGeehan, Hepregen's Vice President of Operations. The partnership will focus on research and development efforts aimed at defining: (1) basic concepts regarding the potential for new micro-liver products and (2) new applications and assay methodologies for Hepregen's existing micro-liver products that are already transforming pharmaceutical product development. PDF

August 5, 2013 Hepregen Corporation Announces Appointment of Dr. Michael Holsapple as Vice President of Toxicology Product Development

Hepregen Corporation, developer of next generation HepatoPacTM and HepatoMuneTM products, announced today the appointment of Dr. Michael P. Holsapple as Vice President of Toxicology Product Development. This appointment of Dr. Holsapple, who will also retain his position at Battelle Memorial Institute ("Battelle"), was accomplished as a part of an investment and commercial development strategy co-elaborated by senior management at Hepregen and Battelle. PDF

July 31, 2013 Hepregen Corporation Announces Appointment of Martin Joyce as Vice President and Chief Financial Officer

Hepregen Corporation, developer of next-generation HepatoPac™ and HepatoMune™ products, announced today the appointment of Martin J. Joyce as Vice President of Finance and Administration, and Chief Financial Officer. This appointment adds a highly experienced expert in finance to Hepregen's senior management team. Mr. Joyce arrives at Hepregen as a member of Danforth Advisors group, a firm specializing in providing experienced finance and accounting personnel to emerging growth companies.

Mr. Joyce's professional background includes C-level leadership roles in public and private, medical device, biotechnology and pharmaceutical companies from start-up stage to those generating $500 million in annual revenue. He has extensive experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. PDF

May 30, 2013 QPS Holdings, LLC and Hepregen Corporation Announce HepatoPac™ Commercial Partnership. Agreement Provides for Co-Promotion, Marketing and Sales of Services Utilizing Hepregen's Proprietary HepatoPac™ Products for Drug Metabolism and Pharmacokinetic Applications.

QPS Holdings, LLC, a US-headquartered contract research organization ("CRO"), and Hepregen Corporation, developer of HepatoPac™ and HepatoMune™  "liver-in-a-dish" products, announced today the execution of an agreement between the companies that provides QPS a license to offer drug metabolism and pharmacokinetic ("DMPK") services to its clients using Hepregen's unique, paradigm-shifting products. The agreement provides for offerings in both North America and Europe. The agreement also creates a marketing and sales partnership between the companies, providing for co-promotion of the HepatoPac™-associated DMPK services. This arrangement is the first such partnership in the field for both companies.

QPS expects to begin offering metabolite identification, profiling, and clearance studies to North American customers before the end of June, and to European customers in the third calendar quarter of this year using HepatoPac™ products. The North American services will be offered from its well established DMPK department in Newark, Delaware, and its newly established DMPK Hepatic Biosciences division based at the Hamner Institutes in Research Triangle Park, North Carolina, using rat, dog, monkey and human HepatoPac™ products. PDF

May 28, 2013 Hepregen Announces Issuance of Its First Patent Protecting Manufacturing Methods of HepatoPac™ and Related Products. Issued Claims Add Years of Protection for Unique, Paradigm-Shifting HepatoPac™ Products.

Hepregen Corporation announced today the issuance of a U.S. patent by the United States Patent and Trademark Office ("USPTO") that protects a key element of the method the Company uses to manufacture its HepatoPac™ and related products. All 20 inventive claims in the original patent application were issued. This patent, entitled Systems and Methods for Micro-Contact Stamping along with Hepregen's foundational patents, which were licensed from the Massachusetts Institute of Technology ("MIT"), ensure product protection for years to come.

Dr. Jack McGeehan, Hepregen's Vice President of Operations and named inventor on the newly issued patent, said, "Hepregen is very pleased by the rapid and positive USPTO review of this patent application. The issued claims protect both the structure and method of use of a device absolutely essential to the reproducible manufacture of Hepregen's unique product portfolio."  PDF

March 18, 2013 Qualyst Transporter Solutions, LLC and Hepregen Corporation Execute Letter of Understanding. Agreement Provides First Step to Partnering Arrangement Supporting Use of Qualyst's Patented B-CLEAR® Technology in Combination with Hepregen's Proprietary HepatoPac™ Products.

Qualyst Transporter Solutions, LLC and Hepregen Corporation announced today, at the American Association of Pharmaceutical Scientists Workshop on Drug Transporters in ADME, the execution of a Letter of Understanding ("LOU") between the companies that supports a collaborative application development effort, and permits Hepregen to utilize Qualyst's patented B-CLEAR® technology for applications involving hepatic transporter proteins in experiments to be conducted with certain key customers. This LOU also serves as a preamble to a broader partnering arrangement being negotiated between the companies, enabling the use of Hepregen's HepatoPac™ products for routine hepatic transporter protein analysis.

"This combination of our two unique proprietary technologies will provide the pharmaceutical industry with a superior tool for defining how transport of drugs and their metabolites affect the disposition and toxicologic properties of candidate drugs in development," commented Dr. Vincent Zurawski, Hepregen's president and chief executive, adding, "Hepregen is delighted with the opportunity to work closely with Qualyst, the clear industry leader in hepatic transporter analysis." PDF

June 27, 2012 Hepregen Corporation Receives National Science Foundation Grant Under SBIR Phase II-B Program.

Hepregen Corporation, a leading provider of bioengineered solutions for drug development, announced today that the company has received a grant for $500,000 from the National Science Foundation under the SBIR Phase II-B Program. This latest award, along with a Challenge Grant from the National Institutes of Health (NIH), a Mass Life Science Center Small Business Matching Grant and earlier grant awards, total nearly $3.0M in state and federal non-dilutive financing.

“As an enabling technology, the HepatoPac™ platform provides high-value information to the pharmaceutical industry,” commented Bonnie Fendrock, Hepregen’s President and CEO. “Creating predictive in vitro models is an important area of opportunity in drug development. This NSF grant allows us to expand our HepatoPac™ offering to include other preclinical species, which is important in refining and reducing animal studies during drug development. We are very excited by the work that we have done to date with pharmaceutical companies who recognize the potential of HepatoPac™, not only as a predictive platform, but also as an enabling technology in drug discovery.”.   PDF

November 2, 2011 Hepregen Corporation and Partners Present Findings at Key Research Meeting. HepatoPac™ Liver Model is touted for its Value to Predict Clinical Parameters of Commercially Available Drugs.

At the annual meeting of the International Society for the Study of Xenobiotics (ISSX), Hepregen Corporation, and two of its pharmaceutical customers, Boehringer Ingelheim Pharmaceuticals, Inc. and Elan Pharmaceuticals presented new preclinical data in poster presentations that tested Hepregen’s proprietary microliver technology platform, HepatoPac™for predicting clearance of drugs which are slowly removed by the liver. Of the commercially available drugs tested, 89 percent were predicted correctly (within two-fold of reported clinical values), while the remaining drugs were within three-to-four fold. Suspension hepatocytes typically used for this type of study do not turn over these drugs sufficiently to make this determination.

These data demonstrated that Hepregen’s HepatoPac™ liver model can be used effectively to predict the clearance of low turnover drugs in humans.   PDF

May 26, 2011 Hepregen Corporation Awarded Massachusetts Life Sciences Center 2011 Small Business Matching Grant. Company receives $500,000 grant; continues growth through adoption of its microliver platform, HepatoPac™ by leading biopharmaceutical companies.

The Massachusetts Life Science Center announced yesterday that Hepregen Corporation, a leading provider of bioengineered solutions that increase success in drug development in order to improve patient safety, was awarded a $500,000 grant as part of the Small Business Matching Grants program established by the Life Sciences Act of 2008. The Center’s program, launched in January 2010 as part of the state’s ten-year, $1 billion Life Sciences Initiative, leverages federal small business grant funding that early-stage life sciences companies in the Commonwealth have received for their work in life sciences research and development, commercialization and manufacturing.

Hepregen’s lead product HepatoPac™ launched in March 2011, is a microliver platform for use in clearance predictions, metabolite profiling, transporter studies, drug-drug interactions, and toxicity determination during the drug development process. The utility of HepatoPac™ in ADME/Tox applications is being validated and adopted by several leading biotechnology and pharmaceutical companies. In an announcement earlier this year, Hepregen detailed the expansion of its collaboration with Boehringer Ingelheim for the integration of HepatoPac™ into drug discovery and development programs.  PDF

May 25, 2011 Massachusetts Life Sciences Center Announces 2011 Small Business Matching Grant (SBMG) Program Awards. Center Awards $2 million to foster job growth and technology commercialization in the Massachusetts Life Sciences Supercluster.

The Massachusetts Life Sciences Center’s Board of Directors (“the Center”) today awarded $2 million in Small Business Matching Grants to four life sciences companies. Each company will receive $500,000 from the Center that matches federal small business grant funding that the companies have been awarded previously. The grants represent the second round of awards issued under the Center’s Small Business Matching Grant (“SBMG”) Program, established by the Life Sciences Act of 2008. Three companies received $1.5 million in grants through the Center’s first round of awards in May of 2010.
The Center’s Small Business Matching Grant Program, launched in January 2010 as part of the state’s ten-year, $1 billion Life Sciences Initiative, leverages federal small business grant funding that early-stage life sciences companies in the Commonwealth have received for their work in life sciences research and development, commercialization and manufacturing. Goals of the Center’s program include the creation of jobs in Massachusetts through the commercialization of products with high potential for market adoption and penetration. PDF

March 10, 2011 Hepregen Corporation Presents Results of Liver Toxicity Study at Annual Meeting of The Society of Toxicoloty. Hepregen’s Microliver Platform, HepatoPac™ Provides Increased Confidence in Drug Development to Impact Patient Safety.

At the 50th Anniversary of the Annual Meeting of Society of Toxicology (SOT), Hepregen Corporation announced today the successful use of its HepatoPac™ platform in an in vitro study demonstrating the species-specific liver toxicity of Fialuridine (FIAU).  The results of the study are being presented today in a poster session. Hepregen Corporation is a leading provider of bioengineered solutions that increase success in drug development in order to improve patient safety.

HepatoPac™ is a microliver platform for use in clearance predictions, metabolite profiling, transporter studies, and toxicity determination during the drug development process. Hepregen’s HepatoPac™ products will be available through its services model initially and then later this year through direct product sales. Researchers from Hepregen Corporation, in collaboration with Alnylam Pharmaceuticals, investigated the acute and chronic toxicity profiles of FIAU and several analogues in Human and Rat HepatoPac™. Using multiple endpoints, FIAU exhibited acute (4 day) and chronic (15 day) dose-dependent toxicity in human HepatoPac™. The toxicity was specific to FIAU alone, whereas other nucleoside analogues did not cause toxicity to the same extent. By contrast, Rat Hepatocytes in the HepatoPac™ platform were not affected by FIAU in the short term and were only mildly impacted chronically, mimicking the species specific in vivo observations.   PDF

March 3, 2011 Hepregen Corporation Announces Commercial Launch of HepatoPac™ Microliver Platform for In Vitro ADME/Tox Applications.

Hepregen Corporation, a leading provider of bioengineered solutions that increase success in drug development in order to improve patient safety, will launch its proprietary technology platform, HepatoPac™, at the SOT 50th Anniversary Annual Meeting and ToxExpo in Washington, D.C. on March 7, 2011.   PDF

January 6, 2011 Hepregen Corporation Expands Agreement with Boehringer Ingelheim for the Adoption of HepatoPac™.

Hepregen Corporation, a leading provider of bioengineered solutions to improve patient outcomes, announced today that it has extended and expanded its agreement with Boehringer Ingelheim Pharmaceuticals, Inc. for the adoption of its proprietary technology platform, HepatoPac™.

The expansion results from collaborative efforts the two companies began in 2009 aimed at evaluating HepatoPac™ for ADME/Tox applications. Under the terms of the new agreement, Hepregen will work with Boehringer Ingelheim Pharmaceuticals, Inc. to integrate HepatoPac™ into drug discovery and development programs.  PDF

January 13, 2010 Hepregen Corporation Receives SBIR Phase II Grant from the National Science Foundation and Presents Corporate Update at OneMedForum.

Hepregen Corporation, a leading provider of bioengineered solutions for drug development, announced today that it has received a Phase II SBIR grant from the National Science Foundation for $500,000. This latest award, in addition to the company’s receipt of a prestigious Challenge Grant from the National Institutes of Health (NIH), along with earlier grant awards, approaches $2.0M in federal funding. Hepregen will also be a featured speaker this afternoon at OneMedForum, where CEO Bernadette (Bonnie) Fendrock will highlight the company’s successful progress since its Series A financing in 2008 from Battelle Ventures, as well as outline important milestones for 2010 and beyond. PDF

February 25, 2009 Battelle Ventures Spins Out Life Science Company from MIT, Committing $5 Million in Series A Funding to Hepregen Corp.

Battelle Ventures, LP, has spun out Hepregen Corporation from the Massachusetts Institute of Technology (MIT), with a commitment of a $5-million Series A investment from the fund and its Tennessee affiliate, Innovation Valley Partners. The company, which is developing bioengineered solutions for drug development, received the first $3 million from the funds last summer, leaving an additional $2 million committed and available at management’s request.  PDF